[HTML][HTML] Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations
K Yau, A Dharia, I Alrowiyti, DZI Cherney - Kidney international reports, 2022 - Elsevier
SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus …
Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and
premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart …
premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart …
Atrial cardiomyopathy revisited—evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart …
A Goette, D Corradi, D Dobrev, L Aguinaga… - Europace, 2024 - academic.oup.com
Aims The concept of “atrial cardiomyopathy”(AtCM) had been percolating through the
literature since its first mention in 1972. Since then, publications using the term were …
literature since its first mention in 1972. Since then, publications using the term were …
The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta …
MU Ali, GBJ Mancini, D Fitzpatrick-Lewis… - Canadian Journal of …, 2022 - Elsevier
Background Evidence for the cardiorenal risk reduction properties of antihyperglycemic
medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 …
medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 …
Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
JW Ostrominski, J Thierer, BL Claggett, ZM Miao… - Heart Failure, 2023 - jacc.org
Background Cardio-renal-metabolic (CRM) conditions are individually common among
patients with heart failure (HF), but the prevalence and influence of overlapping CRM …
patients with heart failure (HF), but the prevalence and influence of overlapping CRM …
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
A Morissette, EE Mulvihill - Trends in Endocrinology & Metabolism, 2024 - cell.com
Individuals with excessive adipose tissue and type 2 diabetes mellitus (T2DM) face a
heightened risk of cardiovascular morbidity and mortality. Metabolic surgery is an effective …
heightened risk of cardiovascular morbidity and mortality. Metabolic surgery is an effective …
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 …
A Ahmad, H Sabbour - Cardiovascular Diabetology, 2024 - Springer
Background Randomized controlled trials and real-world studies suggest that combination
therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like …
therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like …
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
MU Ali, GBJ Mancini, D Fitzpatrick-Lewis… - Cardiovascular …, 2024 - Springer
Abstract Background The 2022 Canadian Cardiovascular Society (CCS) cardiorenal
guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors …
guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors …